CCR2 and metabolic dysfunction-associated steatohepatitis: The pharmacological inhibition of CCR2 with CVC has recently been used for the clinical treatment of NASH.25 However, the beneficial effects of CVC on human fibrosis were questioned in a recent phase III clinical trial.29 Investigations that explore the cellular and molecular mechanisms of CVC in liver fibrosis may help to explain the controversial clinical and experimental data.